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Among patients with non-small-cell lung cancer (NSCLC), those with pathological stage I have the best expectation of survival;
however, survival is reduced to less than 50% in the long term. At present, it is unclear when patients can be reasonably defined as
cured, and if they experience a higher incidence of malignant/nonmalignant diseases and a lower expectation of survival than the
general population. A total of 134 stage I NSCLC patients, who had undergone resection at the Thoracic Surgery Unit of the General
Hospital of Verona (north-eastern Italy) from October 1987 to December 1993, were still disease-free at 5 years. These subjects
were further followed up, and morbidity and mortality rates were compared with those recorded in the general population of the
same geographical area. The standardised incidence ratios (SIRs) for all malignancies and for lung cancer were higher than expected
(2.39, 95% CI¼1.6–3.5, Po0.001; 10.1, 95% CI¼6.2–15.6, Po0.0001, respectively). The standardised mortality ratio (SMR) was
also significantly increased (1.73, 95% CI¼1.1–2.6, P¼0.013). The excess mortality could be entirely explained by an increase in
mortality from lung cancer (5.7, 95% CI¼2.8–10.1, Po0.0001). This study shows that patients, resected for pathological stage I
NSCLC and tumour-free after 5 years, have a higher incidence of new lung cancer compared with the general population, which in
turn determines an excess in all-cause mortality in the following years.
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Lung cancer is one of the leading causes of cancer death all over
the world; as in most industrialised areas, also in the Veneto region
(north-eastern Italy) the incidence accounts for about 75 cases per
100000 inhabitants per year (Venetian Tumour Registry, 1999).
Among patients with non-small-cell lung cancer (NSCLC), those
with pathological stage I have the best expectation of survival,
since they do not present major negative prognostic factors such as
incomplete resection, positive lymph nodes, distant metastases. At
present, the standard therapy of stage I NSCLC is radical surgery.
However, in the long term, the all-cause survival rate is reduced to
less than 50%, due to deaths from relapses, new cancers and
nonmalignant competing events.
It is unclear when patients can be reasonably defined as cured
from their initial lung cancer; it is also unknown if they have a
higher incidence of malignant and nonmalignant diseases or
experience the same expectation of survival when compared to the
general population.
To answer these questions, a series of patients with pathological
stage I NSCLC, who had undergone resection in a single institution
and were disease-free at 5 years, was further followed up, and
morbidity and mortality rates were compared with the rates
recorded in the general population of the same geographical
area.
PATIENTS AND METHODS
From October 1987 to December 1993, 246 consecutive patients
underwent thoracotomy at the Thoracic Surgery Unit of the
General Hospital of Verona, north-eastern Italy, for pathologically
confirmed stage I (T1-2 N0 M0) NSCLC. None of the patients
received neoadjuvant or adjuvant chemo/radiotherapy.
The hospital charts of all patients were reviewed; for those who
were not routinely followed up, follow-up data were obtained by
personal contact, or by a questionnaire sent to the family doctor,
or relatives of a deceased patient. Information on disease
occurrence, life status and cause of death, if any, was retrieved
for all patients. Pathological slides were reviewed by a pathologist
(PG) without knowledge of the clinical outcome.
This study focused on the outcome of 134 patients, out of the
initial 246, who were disease-free at least 5 years after resection.
These patients were followed up until 31 December 1999.
Disease and causes of death were coded according to the
International Classification of Diseases, Ninth Revision (ICD9).
The following health outcomes were considered: new diagnosis of
cancer from any site (ICD9 code¼140–208), new diagnosis of
cancer of the trachea, bronchi and lung (ICD9 code¼162), and
death from any cause (ICD9 code¼0–999).
Incidence and mortality rates in the cohort of 134 patients were
compared with rates recorded in the Veneto region, the admin-
istrative area including Verona, through indirect standardisation
(Rothman and Greenland, 1998). Received 15 July 2002; revised 12 March 2003; accepted 26 March 2003
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Tumour Registry (1999) and regional mortality rates were obtained
from the Italian Institute of Statistics (Italian Institute of Statistics,
ISTAT, 2000).
Statistical analysis
Standardised incidence ratios (SIRs) and standardised mortality
ratios (SMRs) were computed by means of the program PYRS
(person-years) version 1.3 (Coleman et al, 1986). Statistical
significance of SMRs and SIRs was evaluated by the Poisson
two-sided test (Verlato et al, 1999), and 95% confidence intervals
(CI) were calculated by the exact method (Breslow and Day, 1987).
Survival curves were estimated by the Kaplan–Meier method. All-
cause survival time was defined as the time from surgery to death
from any cause, disease-related survival time as the time from
surgery to death from lung cancer, and disease-free survival time
as the time from surgery to recurrence of the disease. When
computing disease-related survival and disease-free survival,
deaths from other causes were considered as censored observa-
tions. To allow graphic evaluation of the excess mortality, observed
survival, estimated by the Kaplan–Meier method, was presented
together with expected survival. The latter was computed by
applying to the cohort under study age- and sex-specific mortality
rates recorded in the general population of the area (Hakulinen,
1982).
RESULTS
Data on complete survival, disease-related survival and disease-
free survival times could be obtained for all 134 patients (18
females and 116 males). Median age at diagnosis was 62 years
(range 35–80), and median follow-up was 96 months (range 61–
144).
The 5- and 10-year disease-free survival percentages of the
entire initial group (246 patients) were 62 and 49%, respectively;
therefore, the 10-year cumulative risk of relapse was increased by
34% compared to that at 5 years. The 5- and 10-year disease-
related survival percentages were 67 and 57%, respectively. All-
cause survival percentages were 62 and 43%, respectively.
Beyond the first 5 years of follow-up, out of 134 patients 26
(19.4%) presented a second cancer, either lung cancer (n¼17),
other types of malignancies (n¼6) or both (n¼3), while the
expected number was 10.87. The SIR (26/10.87¼2.39, 95%
CI¼1.6–3.5) was significantly higher than expected (Po0.001)
(Figure 1).
Of these patients, 20 (14.9%) were diagnosed to have a new
NSCLC appearing therefore after a 5-year tumour-free interval;
this value was 10 times higher than that expected (SIR¼
20/1.98¼10.1, 95% CI¼6.2–15.6, Po0.0001).
Among the 134 patients, nine (6.7%) presented a second
malignancy other than lung cancer. The SIR of extrapulmo-
nary tumours after 5 years was comparable to that expected
(9/9.7¼0.93, 95% CI¼0.4–1.8, P¼1).
Overall, 23 patients died, while the expected number in the same
series was 13.27. The SMR (23/13.27¼1.73, 95% CI¼1.1–2.6) was
significantly increased (P¼0.013); the excess mortality could be
entirely explained by an increase in mortality due to all types of
cancer (SMR¼15/5.99¼2.5, 95% CI¼1.4–4.1, P¼0.002). A more
detailed analysis highlighted that the excess mortality was confined
to deaths from lung cancer, which was nearly six times higher than
expected (11/1.94¼5.7, 95% CI¼2.8–10.1, Po0.0001).
After 10 years of follow-up, the difference between the observed
and the expected proportion surviving was about 0.1 (Figure 2).
The two curves started to diverge after about 7 years of
follow-up.
DISCUSSION
This study evaluated the outcome of a series of consecutive
patients with pathological stage I NSCLC who were free from their
lung tumour 5 years after surgery.
In our series (Pasini et al, 2002), as well as in other reports, at 10
years the disease-related survival decreased by 10% compared to
that at 5 years (from 67 to 57%) (Flehinger et al, 1992; Ichinose
et al, 1993; Harpole et al, 1995; Martini et al, 1995). Most of the
recurrences occurred in the first two or three years after diagnosis;
since then, however, patients continued to relapse and die at a rate
of 2–5%. In the period lasting from 5 to 10 years, the risk of
relapse increased from 38 to 51%, a relative increment of 34%.
There is no general agreement on how these late events are to be
classified (i.e. recurrences or second lung cancers). In our opinion,
a disease-free interval of 5 years seems appropriate for the
definition of second lung primaries, although the crucial point is
the assessment of their incidence and impact on survival.
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Figure 1 Standardised incidence ratios (SIRs) and standardised mortality
ratios (SMRs) in the 134 patients who were alive and free from relapses of
lung cancer 5 years after resection. Indirect standardisation was
accomplished using as reference rates recorded in the Veneto region.
Columns are values; bars are confidence intervals. ca.¼cancer.
70
75
80
85
90
95
100
5              6             7              8 9 10 11
Years of follow-up
S
u
r
v
i
v
a
l
 
(
%
)
N   134          130          96            67            57             28           16
Figure 2 Kaplan–Meier estimates of survival probability (thick line) in a
series of 134 patients who underwent surgery for lung cancer and who
were apparently ‘cured’ after 5 years. Expected survival in the series
according to mortality in the general population of the Verona area is also
shown (thin line).
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patients died also of competing events such as cardiovascular
diseases, other non-neoplastic diseases and different types of
tumours; eventually, the 10-year crude survival rate was only 43%.
Following this consideration, some questions may be raised in
the subset of stage I NSCLC patients disease-free at 5 years. The
first is whether this interval is sufficient to declare a patient cured;
the second is whether these patients have a life expectancy
equivalent to that of the general population.
To our knowledge, there are scanty data in the literature
concerning the long-term outcome of such a cohort of patients; in
particular, it is unclear whether the mentioned yearly recurrence
rate (2–5%) is superior compared to the incidence of new lung
cancers usually detected in the general population.
For this reason, we have compared the SIR for all types of
cancers and the SMR of our study population with those of the
general population of the Veneto region. This region is located in
the north-east of Italy, an industrialised area in which lung cancer
incidence is among the highest in Europe (about 75 cases per
100000 inhabitants per year).
In the observed group, the SIR for all types of cancer was 2.4
times higher than that expected (Po0.001). The number of
extrapulmonary tumours was similar to that of the control
population (SIR¼0.93), while the occurrence of second lung
primaries in the study population was 10 times higher than in the
controls (Po0.0001). Therefore, the excess of tumours was entirely
due to second lung cancers.
This increased incidence of second lung primaries was not
associated with confounding factors such as radiotherapy (i.e. in
Hodgkin’s disease) or chemotherapy, since none of these patients
had received adjuvant treatment.
As for mortality, we found that the overall SMR was about 70%
higher than that expected according to the mortality rates of the
general population (P¼0.013). Further analysis of the data
elucidated the role of the various causes of death. It could be
shown that second lung cancers caused in the study population an
excess of mortality of about six times (Po0.0001), while mortality
from other causes was similar. Moreover, as already reported, only
a minority of the patients (about 30%) with second lung cancers
survived beyond 3 years, mainly because of their advanced stage
(Thomas and Rubinstein, 1993; Johnson, 1998).
The worse outcome can be seen in Figure 2, where the difference
between observed and expected survival is about 0.1 after 10 years
of follow-up.
In other words, most of the patients disease-free at 5 years can
be considered cured; nevertheless, in a non-negligible proportion
of them, second lung primaries showed an increased incidence
with a low curability rate and were by far the leading cause of
death.
These observations need validation with larger cooperative data,
because, if confirmed, may provide new hints about the biological
behaviour of the tumour.
They also emphasise the need for continued surveillance when
planning the follow-up of patients in an attempt to detect new
lesions at an early stage, when there are real chances of cure. On
the other hand, the benefits of earlier intervention may represent a
subset with differences in the biology of disease or other unknown
factors (Thomas and Rubinstein, 1990; Faber, 1993; Antakli et al,
1995; Martini et al, 1999; Downey, 1999). Moreover, in the setting
of prevention, other issues have to be considered, such as smoking
cessation, carcinogenesis/chemoprevention studies and the use of
new genetic tools able to characterise molecular markers of risk
and drug activity. Integration of these strategies is necessary to
reduce lung cancer mortality rate.
In conclusion, this study shows that patients with pathological
stage I NSCLC tumour-free after 5 years, when compared with the
general population, had a higher incidence of new lung cancers,
which in turn explains the higher mortality observed in the
following years.
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